Kane Biotech Inc. (TSXV:KNE)
Canada · Delayed Price · Currency is CAD | Market Cap | 8.17M |
| Revenue (ttm) | 574.87K |
| Net Income (ttm) | -3.26M |
| Shares Out | 181.60M |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 106,387 |
| Average Volume | 224,386 |
| Open | 0.0400 |
| Previous Close | 0.0450 |
| Day's Range | 0.0400 - 0.0450 |
| 52-Week Range | 0.0250 - 0.1150 |
| Beta | 0.18 |
| RSI | 61.30 |
| Earnings Date | Apr 28, 2026 |
About Kane Biotech
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, a biofilm destabilizing formula with continuous activity; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG) for treating wounds and otic infections. Its wound care product portfolio inclu... [Read more]
Financial Performance
Financial StatementsNews
Kane Biotech Announces Closing of Private Placement Offering with an Insider of the Company
Not for distribution to U.S. news wire services or dissemination in the United States Not for distribution to U.S. news wire services or dissemination in the United States
Kane Biotech Presents New Data at Innovations in Wound Healing Annual Meeting
WINNIPEG, Manitoba, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) announces that it presented new clinical and scientific data at the Innova...
Kane Biotech Wins Approval For Revyve Antimicrobial Wound Gel Spray In Canada
(RTTNews) - Kane Biotech Inc. (KNBIF.OB) announced that Health Canada has approved its revyve Antimicrobial Wound Gel Spray, providing Canadian clinicians and patients with a new option for managing b...
Kane Biotech Announces Third Quarter 2025 Financial Results
WINNIPEG, Manitoba, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announced its third quarter 2025 financial results.
Kane Biotech Announces $800K Private Placement To Advance Wound Care Portfolio
(RTTNews) - Kane Biotech Inc. (KNE.V), on Thursday, announced a non-brokered private placement offering of up to 16 million common shares, priced at $0.05 per share for gross proceeds of up to $800,00...
Kane Biotech Announces New Private Placement Offering
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the...
Kane Biotech Presents revyve® Data at Diabetic Foot and Southern Region Burn Conferences
WINNIPEG, Manitoba, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane Biotech” or “Kane”) today announced new clinical and pre-clinical data demonstrating the performance of its ...
Kane Biotech Completes U.S. FDA 510(k) Submission for revyve® Antimicrobial Wound Cleanser
WINNIPEG, Manitoba, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or the “Company”) today announces that it has completed a U.S. Food and Drug Administration (“FDA”)...
Kane Biotech Completes Enrollment in U.S. Case Series Studies of its revyve® Antimicrobial Wound Gel and Spray
WINNIPEG, Manitoba, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or “Kane”) today announces that it has enrolled 28 participants in its revyve® Antimicrobial Wound ...
Kane Biotech reports Q2 results
Kane Biotech Announces Second Quarter 2025 Financial Results
WINNIPEG, Manitoba, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announced its second quarter 2025 financial results.
Kane Biotech to Present at Advanced Wound Care Summit USA
WINNIPEG, Manitoba, July 14, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane Biotech” or “Kane”) announces today that Kane Biotech's Interim Chief Executive Officer, Dr. Robert Huizinga...
Philip Renaud files Early Warning Report in respect of Kane Biotech Inc.
MILAN , June 27, 2025 /CNW/ - Philip Renaud (22 Corso Venecia , Milan, Italy 20122), a director of Kane Biotech Inc. (the "Corporation"), today announces that he has subscribed for a 3% unsecured conv...
Kane Biotech Announces Conversion of Demand Loan from Insider into an Unsecured Convertible Debenture and Annual General Meeting Voting Results
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, June 26, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotec...
Kane Biotech Provides Further Corporate Update
WINNIPEG, Manitoba, June 18, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) provides updates on its reorganizational phase.
Kane Biotech reports Q1 results
Kane Biotech Announces First Quarter 2025 Financial Results
WINNIPEG, Manitoba, May 29, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces its first quarter 2025 financial results.
Philip Renaud files Early Warning Report in respect of Kane Biotech Inc.
MILAN , May 6, 2025 /CNW/ - Philip Renaud (22 Corso Venecia , Milan, Italy 20122), a director of Kane Biotech Inc. (the "Corporation"), today announces that he has acquired 10,000,000 common shares of...
Kane Biotech Announces Closing of Private Placement Offering and Loan with Insiders of the Company
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, May 05, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Ka...
Kane Biotech Announces Fourth Quarter and Full Year 2024 Financial Results, Narrows Strategic Focus and Makes Leadership Change
WINNIPEG, Manitoba, April 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSXV: KNE , OTCQB: KNBIF) ("Kane Biotech", "Kane" or the "Company") today announced its fourth quarter and full year 2024 fin...
Kane Biotech Announces Fourth Quarter and Full Year 2024 Financial Results, Narrows Strategic Focus and Makes Leadership Change
WINNIPEG, Manitoba, April 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) today announced its fourth quarter and full year 2024 financ...
Kane Biotech Announces New Agreement with Outside the Box Capital Inc.
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba,, April 11, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (“Kane Biotech” ...
Kane Biotech Secures IRB Approval to Launch Innovative DispersinB® Acne Trial
Kane to work with the University of Miami to study DispersinB® Acne Cleanser in mild to moderate Acne Vulgaris Kane to work with the University of Miami to study DispersinB® Acne Cleanser in mild to m...
Kane Biotech Announces Canadian Distribution Agreement With Best Buy Medical for revyve™ Antimicrobial Wound Gel
Strategic Partnership Expands Access to Innovative Wound Care Solution Across Canada Strategic Partnership Expands Access to Innovative Wound Care Solution Across Canada
Kane Biotech Announces Second and Final Closing of Private Placement Offering
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “K...